| NASDAQ (usa) |   | 6715.56 | -12.11 | -0.18% | 
| FTSE 100 (london) |  | 7487.96 | -5.12 | -0.07% | 
| DAX (german) |   | 13465.51 | 235.94 | 1.78% | 
| NIKKEI 225 (japan) |   | 22420.08 | 408.47 | 1.86% | 
| Hang - Seng (hong kong) |   | 28594.06 | 348.52 | 1.23% | 
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |   | 3391.61 | 17.53 | 0.52% | 
| KOSPI (korea) |   | 2556.47 | 33.04 | 1.31% | 
| All Ordinaries (australia) |   | 6005.30 | 28.90 | 0.48% | 
| BOVESPA (brazil) |   | 74092.76 | -215.73 | -0.29% | 
ImmunoGen Inc (NASDAQ: IMGN)
                                    	IMGN Technical Analysis
                                    
                                    
    5
    
    
    
    
									| As on 9th Feb 2024 IMGN STOCK Price closed @ 31.23 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.87 & Strong Buy for SHORT-TERM with Stoploss of 5.57 we also expect STOCK to react on Following IMPORTANT LEVELS. | 
IMGNSTOCK Price
| Open | 31.24 | Change | Price | % | 
| High | 31.25 | 1 Day | 0.00 | 0.00 | 
| Low | 31.22 | 1 Week | 1.91 | 6.51 | 
| Close | 31.23 | 1 Month | 1.36 | 4.55 | 
| Volume | 48606862 | 1 Year | 25.11 | 410.29 | 
| 52 Week High 29.95 | 52 Week Low 3.67 | ||||
    NASDAQ USA Most Active Stocks
                    | AMRS | 0.14 | 100.00% | 
| WBA | 11.98 | 0.50% | 
| HBIO | 0.63 | 40.00% | 
| CMBM | 3.75 | 27.12% | 
| NVDA | 202.89 | -2.00% | 
| BYND | 1.65 | -10.33% | 
| ONDS | 6.29 | -6.81% | 
| LMDX | 0.02 | 0.00% | 
| OPEN | 7.34 | -4.05% | 
| AKTS | 0.04 | 0.00% | 
NASDAQ USA Top Gainers Stocks
                    
                NASDAQ USA Top Losers Stocks
                    
                | IMGN Daily Charts | IMGN Intraday Charts | Whats New @ Bazaartrend | IMGN Free Analysis | 
|  | 
IMGN Important Levels Intraday
                                    | RESISTANCE | 31.29 | 
| RESISTANCE | 31.27 | 
| RESISTANCE | 31.26 | 
| RESISTANCE | 31.25 | 
| SUPPORT | 31.21 | 
| SUPPORT | 31.20 | 
| SUPPORT | 31.19 | 
| SUPPORT | 31.17 | 
IMGN Forecast  October 2025
                                    | 4th UP Forecast | 34.18 | 
| 3rd UP Forecast | 33.23 | 
| 2nd UP Forecast | 32.65 | 
| 1st UP Forecast | 32.06 | 
| 1st DOWN Forecast | 30.4 | 
| 2nd DOWN Forecast | 29.81 | 
| 3rd DOWN Forecast | 29.23 | 
| 4th DOWN Forecast | 28.28 | 
     IMGN Weekly Forecast
                                    
                                    
                                | 4th UP Forecast | 33.08 | 
| 3rd UP Forecast | 32.49 | 
| 2nd UP Forecast | 32.12 | 
| 1st UP Forecast | 31.75 | 
| 1st DOWN Forecast | 30.71 | 
| 2nd DOWN Forecast | 30.34 | 
| 3rd DOWN Forecast | 29.97 | 
| 4th DOWN Forecast | 29.38 | 
IMGN Forecast2025
                                    | 4th UP Forecast | 84.49 | 
| 3rd UP Forecast | 67.41 | 
| 2nd UP Forecast | 56.85 | 
| 1st UP Forecast | 46.29 | 
| 1st DOWN Forecast | 16.17 | 
| 2nd DOWN Forecast | 5.61 | 
| 3rd DOWN Forecast | -4.95 | 
| 4th DOWN Forecast | -22.03 | 
                                        ImmunoGen Inc ( NASDAQ USA Symbol : IMGN ) 
Sector : Healthcare And Other Stocks in Same Sector
                                    
                                    
                                Sector : Healthcare And Other Stocks in Same Sector
IMGN Other Details
                    | Segment | EQ | |
| Market Capital | 1198237568.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
IMGN Address
                                 |  | ||
                                        IMGN Latest News
                                    
                                    
                                    IMGN Business Profile
   
	 ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. Address: 830 Winter Street, Waltham, MA, United States, 02451-1477 
	
            
            © 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
 
	   Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

